• Strong top-line growth, underlying profitability and cash generation
• Four assets in pivotal / Phase 3 trials
• Pathway to launch new Precision Medicine products

Telix Pharmaceuticals Ltd reported strong financial performance in 2025, with 56% year-over-year revenue growth to $804M. The company's Precision Medicine revenue grew 22% to $622M, and the acquisition of RLS Radiopharmacies added $170M in revenue. Telix is making significant investments to drive future value creation, including over $500M across R&D, commercial infrastructure, and strategic initiatives. The company has a robust pipeline with four assets in pivotal/Phase 3 trials, including TLX591-Tx for prostate cancer, TLX101-Tx for glioblastoma, TLX250-Tx for renal cell carcinoma, and TLX090-Tx for bone pain. Telix is also making progress on its Precision Medicine portfolio, with regulatory submissions for TLX101-Px (Pixclara) in the U.S. and Europe, and the acceptance of the Illuccix NDA in China. The company has also entered a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies.

Telix provided revenue guidance for FY 2026 in the range of $950M to $970M, representing ~25% growth in Precision Medicine revenue and the full-year contribution from the RLS Radiopharmacies acquisition. The company's R&D guidance for FY 2026 is in the range of $200M to $240M, with increased allocation to the therapeutics pipeline.

Telix is well-positioned for continued growth, driven by the successful launch of new Precision Medicine products, advancement of its late-stage therapeutics pipeline, and strategic collaborations. The company's investments in R&D, commercial infrastructure, and global supply chain will support its long-term growth objectives.